Crescent Biopharma
CBIO
35 hedge funds and large institutions have $7.2M invested in Crescent Biopharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 37 closing their positions.
1,434% more call options, than puts
Call options by funds: $675K | Put options by funds: $44K
0.18% less ownership
Funds ownership: 0.57% → 0.4% (-0.18%)
49% less funds holding
Funds holding: 69 → 35 (-34)
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
92% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 37
93% less capital invested
Capital invested by funds: $111M → $7.2M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$712K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$212K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$140K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$84.7K |
| 5 |
Two Sigma Advisers
New York
|
+$82.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$11.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$9M |
| 3 |
Axa
Paris,
France
|
-$4.76M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$653K |
| 5 |
Millennium Management
New York
|
-$583K |
CBIO Hedge Fund Activity: Q2 2024 in Review
35 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2024, worth a combined $7.2M — down 93% from $111M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CBIO and 3 opened new positions — a net loss of 34 holders — while 16 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $712K. The largest seller was NEA Management Company, exiting entirely with an estimated $11.5M sold.
- 35 institutional investors held Crescent Biopharma (CBIO) as of Q2 2024, down from 69 in Q1 2024.
- Funds reported $7.2M of Crescent Biopharma stock for Q2 2024, down 93% quarter-over-quarter.
- 3 funds opened new Crescent Biopharma positions in Q2 2024 and 37 closed out, a net change of -34 holders.
- The largest Crescent Biopharma buyer in Q2 2024 was Renaissance Technologies, an estimated $712K added.
- The largest Crescent Biopharma seller in Q2 2024 was NEA Management Company, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2024.